Role of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in Management of Cardiovascular-Kidney-Metabolic (CKM) Conditions
Cardiology Clinics · 2025
DOI: 10.1016/j.ccl.2024.12.003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiology Clinics, 2025. Verfasst von Radica Z Alicic und 1 weiteren Autor:innen. Beteiligte Einrichtung: Providence Medical Research Center, Providence Inland Northwest Health, Spokane, WA, USA; Department of Medicine, University of Washington, Seattle, …. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Cardiovascular Diseases, Glucagon-Like Peptide 1, Gastric Inhibitory Polypeptide. Die Arbeit nennt 114 Literaturangaben.
Abstract (Originalsprache)
Use of glucagon-like peptide-1 (GLP-1) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, initially developed as glucose-lowering therapies for the management of type 2 diabetes, continues to expand in parallel with our understanding of their beneficial effects on cardiovascular-kidney-metabolic conditions. Large clinical outcome trials have established GLP-1 receptor agonists as guideline-directed therapies to improve glycemia, achieve, and maintain weight management goals, and mitigate cardiovascular and kidney risk, with early evidence suggesting similar benefits with the dual GIP/GLP-1 receptor agonist tirzepatide.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Providence Medical Research Center, Providence Inland Northwest Health, Spokane, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA. Electronic address: Radica.Alicic@providence.org.
- Providence Medical Research Center, Providence Inland Northwest Health, Spokane, WA, USA; Department of Pharmacotherapy, College of Pharmacy and Pharmaceutical Sciences, Washington State University, 412 E. Spokane Falls…
Zitieren
APA
Alicic, R. Z., & Neumiller, J. J. (2025). Role of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in Management of Cardiovascular-Kidney-Metabolic (CKM) Conditions. Cardiology Clinics. https://doi.org/10.1016/j.ccl.2024.12.003
Vancouver
Alicic RZ, Neumiller JJ. Role of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in Management of Cardiovascular-Kidney-Metabolic (CKM) Conditions. Cardiology Clinics. 2025. doi:10.1016/j.ccl.2024.12.003
BibTeX
@article{Alicic2025,
author = {Alicic, Radica Z and Neumiller, Joshua J},
title = {Role of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in Management of Cardiovascular-Kidney-Metabolic (CKM) Conditions},
journal = {Cardiology Clinics},
year = {2025},
doi = {10.1016/j.ccl.2024.12.003}
}
EUVIMED